Autolus Therapeutics (AUTL) Projected to Announce Quarterly Earnings on Tuesday

Posted by Brenda Bartman on Aug 4th, 2026

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Autolus Therapeutics to announce earnings of ($0.22) per share and revenue of $29.7430 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. The firm had revenue of $26.22 million during the quarter, compared to analysts’ expectations of $26.27 million. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%. On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL traded up $0.12 during trading on Tuesday, hitting $1.95. 1,799,517 shares of the company were exchanged, compared to its average volume of 1,654,223. Autolus Therapeutics has a 1 year low of $1.18 and a 1 year high of $2.52. The company has a market cap of $517.68 million, a price-to-earnings ratio of -1.78 and a beta of 2.07. The firm’s fifty day moving average price is $1.57 and its 200 day moving average price is $1.53.

Hedge Funds Weigh In On Autolus Therapeutics

Hedge funds have recently bought and sold shares of the stock. Schroder Investment Management Group lifted its stake in shares of Autolus Therapeutics by 133.7% during the 3rd quarter. Schroder Investment Management Group now owns 8,433,253 shares of the company’s stock worth $13,409,000 after purchasing an additional 4,824,763 shares during the period. Mak Capital One LLC grew its position in shares of Autolus Therapeutics by 15.3% in the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after purchasing an additional 3,987,727 shares during the period. Armistice Capital LLC grew its position in shares of Autolus Therapeutics by 30.0% in the third quarter. Armistice Capital LLC now owns 15,600,000 shares of the company’s stock valued at $25,428,000 after purchasing an additional 3,600,000 shares during the period. Bank of America Corp DE increased its stake in Autolus Therapeutics by 108.1% in the third quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after purchasing an additional 1,054,458 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Autolus Therapeutics in the third quarter valued at $639,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on AUTL shares. Weiss Ratings lowered shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Wall Street Zen upgraded Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 9th. Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Autolus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

View Our Latest Analysis on Autolus Therapeutics

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.